stockrowNeurogene Inc.
NGNE Healthcare Biotechnology
Neurogene Inc.’s revenue for fiscal 2024 (year ended December 2024) was $925,000.00.
- EPS
- −45.7%
- Free cash flow
- −23.0%
- Total debt
- −66.7%
Quarter to June 2026, against a year earlier
Follow NGNE
Alert me
Neurogene Inc. (NGNE) Altman Z-score
Neurogene Inc.'s Altman Z-score for fiscal 2024 is 8.68, in the safe zone (above 2.99).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2024 | 8.68 | 6.61 |
| FY2018 | 2.07 | — |
How fiscal 2024’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.90 | — | 1.08 | |
| Retained earnings / total assets | (0.78) | — | −1.09 | |
| EBIT / total assets | (0.25) | — | −0.81 | |
| Market value of equity / total liabilities | 15.84 | — | 9.50 | |
| Sales / total assets | 0.00 | — | 0.00 | |
| Altman Z-score | Safe zone | 8.68 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Safe zone | 14.53 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| NGNE Neurogene Inc. | 8.7× |
| ENTX Entera Bio Ltd. compare | 6.2× |
| OVID Ovid Therapeutics compare | 0.2× |
| PBYI Puma Biotechnology, Inc. compare | −4.2× |
| CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR compare | −30.4× |
| FTH Faeth Therapeutics, Inc. compare | — |
| YDES YD Bio Limited compare | — |
| SLBT SL SCIENCE HLDG compare | — |
| CLYM Climb Bio, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets